Product image of Orizal (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Orizal

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Orizal (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxomil and amlodipine, the active ingredient in Orizal, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, helping to lower cardiovascular risk.

GNH India supplies Orizal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Menarini International Operations Luxembourg S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Orizal is a combination antihypertensive that acts on the renin‑angiotensin system and vascular smooth‑muscle tone to control blood pressure.

  • Hypertension: improves blood pressure control when monotherapy is insufficient.
  • Hypertension with isolated systolic pressure elevation: provides additional vasodilation to reduce systolic readings.
  • Hypertension in patients with concomitant peripheral edema: amlodipine‑related edema is mitigated by olf‑based counter‑effects, enhancing tolerability.

How It Works

  • Olmesartan medoxil is an angiotensin‑II receptor blocker that selectively inhibits AT1 receptors, preventing vasoconstriction and aldosterone release. Amlodipine is a dihydropyridine calcium‑channel blocker that relaxes arterial smooth muscle by inhibiting calcium influx, producing vasodilation. The combined effect results in additive blood‑pressure reduction.

Side Effects

Common Side Effects

  • Headache: mild to moderate tension‑type headache.
  • Peripheral edema: swelling of ankles or feet, especially with the calcium‑channel component.
  • Dizziness or light‑headedness: often related to blood‑pressure lowering.
  • Flushing: transient warmth and reddening of the skin.
  • Fatigue: general tiredness not linked to activity level.
  • Nausea: mild stomach upset.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of lips, tongue or airway requiring emergency care.
  • Severe hypotension: symptomatic low blood pressure such as fainting.
  • Acute kidney injury: sudden decline in renal function, especially in patients with pre‑existing kidney disease.
  • Liver enzyme elevations: marked increase in ALT/AST.
  • Myocardial infarction: rare but reported in patients with pre‑existing coronary disease.
  • Hyperkalemia: elevated potassium levels, particularly when combined with potassium‑sparing diuretics.

Precautions & Warnings

Before starting Orizal, consider the following precautions:

  • Renal function assessment: evaluate baseline creatinine and eGFR, adjust if impaired.
  • Hepatic function assessment: check liver enzymes in patients with liver disease.
  • Electrolyte monitoring: monitor potassium levels, especially if on diuretics.
  • Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional.
  • Concomitant antihypertensives: monitor for additive blood‑pressure lowering effects.
  • Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Avoid Interactions

Orizal may interact with several drug classes. Review the following:

Major Interactions (Avoid)

  • Aliskiren: combined use with an ARB can increase risk of renal impairment, hyperkalemia and hypotension.
  • Potassium‑sparing diuretics: may cause dangerous hyper‑kalemia when added to an ARB.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase amlodipine plasma levels, raising risk of hypotension.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
  • Lithium: ARB component can raise lithium concentrations, requiring serum level monitoring.
  • Beta‑blockers: additive blood‑pressure lowering may necessitate dose adjustments.
  • Diuretics: may enhance hypotensive effect; monitor blood pressure and electrolytes.

Frequently Asked Questions

Orizal is a fixed‑dose combination of olmesartan medoxomil and amlodipine that is prescribed to lower high blood pressure (hypertension) when a single agent does not provide adequate control. It is used in adult patients who need both renin‑angiotensin blockade and calcium‑channel mediated vasodilation.

Olmesartan medoxomil is an angiotensin‑II receptor blocker (ARB). It selectively blocks the AT‑1 receptors that mediate the actions of angiotensin‑II, preventing vasoconstriction and the release of aldosterone, which together lower systemic vascular resistance and blood pressure.

The dose of Orizal is individualized by the prescribing clinician based on the patient’s blood‑pressure level, response to therapy and any co‑existing medical conditions. The prescriber determines the appropriate strength and dosing schedule.

Olmesartan medoxomil is classified as pregnancy‑category D and is generally avoided during pregnancy because of potential fetal toxicity. Amlodipine is also not recommended unless clearly needed. Breastfeeding mothers should consult their healthcare provider, as the drugs may pass into milk.

To place an order, submit an enquiry on the Orizal product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Orizal combines an ARB with a calcium‑channel blocker, offering additive blood‑pressure reduction compared with monotherapy. Compared with separate tablets, the fixed‑dose combo can improve adherence. Alternatives include ACE‑inhibitor + CCB combos or ARB + thiazide diuretic combinations, each with distinct efficacy and safety profiles.

Orizal tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not store in areas of high humidity or extreme heat.

Orizal is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing instructions provided by their healthcare professional.

Serious risks include angio‑edema, severe hypotension, acute kidney injury and hyper‑kalemia. Patients should seek immediate medical attention if they experience swelling of the face or throat, fainting, sudden loss of kidney function or markedly elevated potassium levels.

Orizal is contraindicated in patients with known hypersensitivity to olmesartan, amlodipine or any tablet excipients, in those with severe hepatic impairment, and in pregnant women unless the benefits outweigh the risks. It should also be avoided in patients with a history of angio‑edema related to ARB therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT